<DOC>
	<DOCNO>NCT01248975</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy safety add GSK2190915 300mg placebo tablet administer daily fluticasone propionate/salmeterol 250/50mcg inhalation powder administer twice daily uncontrolled asthmatic subject &gt; = 18 year age course 6 week treatment . The secondary objective undertake exploratory analysis efficacy safety add montelukast 10mg administer daily fluticasone propionate/salmeterol 250/50mcg inhalation powder administer twice daily investigate pharmacokinetics pharmacodynamics GSK2190915 uncontrolled asthmatic subject &gt; = 18 year age course 6 week treatment .</brief_summary>
	<brief_title>Safety Efficacy Study Adding GSK2190915 Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Age : 18 year age old Non , former current smoker document smoke history ≤ 10 pack year Asthma diagnosis define National Institutes Health Best FEV1 50 % &lt; 80 % predict normal value For current former smoker , postalbuterol FEV1/FVC ratio &gt; 0.70 Visit 1/1a ( 5:00AM 12:00 noon ) ≥ 12 % ≥200mL reversibility FEV1 Must use FP/SAL 250/50mcg inhalation powder BID least 2 week prior Visit 1 . Must able replace current shortacting beta2agonists albuterol inhalation aerosol Must able willing give write informed consent take part study . Must able willing comply aspect study include completion daily eDiary . Exclusion criterion : History lifethreatening asthma Recent asthma exacerbation Concurrent respiratory disease Recent respiratory infection Liver disease Other concurrent diseases/abnormalities Oral candidiasis Drug allergy Milk protein allergy Immunosuppressive Medications Administration systemic , oral depot corticosteroid within 12 week Visit 1 OATP1B1 substrate within 4 week Visit 1 Cytochrome P450 3A4 ( CYP 3A4 ) Inhibitors Cytochrome P450 3A4 ( CYP 3A4 ) Inducers Investigational Medications Compliance : infirmity , disability , geographical location seem likely ( opinion Investigator ) impair compliance aspect study protocol Affiliation Investigator 's Site</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>GSK2190915</keyword>
</DOC>